Comprehensive Evaluation of Cefiderocol Against Meropenem-Resistant Enterobacterales: Implications for Antimicrobial Research

Study Background and Research Question

Antimicrobial resistance, particularly among Gram-negative Enterobacterales, poses a dire threat to global health. Carbapenem-resistant Enterobacterales (CREs) are classified as critical priority pathogens by the WHO due to limited treatment options and high rates of multidrug resistance. In Europe, resistance rates vary by region and species, with Klebsiella pneumoniae demonstrating particularly concerning rates of carbapenem resistance. The referenced study (Santerre Henriksen et al., 2024) addresses the urgent need to compare the efficacy of novel and existing antibiotics—including cefiderocol—against a large, geographically diverse set of Enterobacterales isolates, many of which are resistant to both meropenem and advanced β-lactam/β-lactamase inhibitor combinations.

Key Innovation from the Reference Study

This research is distinguished by its scale and systematic approach. Over 1,900 Enterobacterales isolates were collected from 49 sites across six European countries, incorporating a significant representation of multidrug-resistant phenotypes. The study is the first to directly compare the in vitro activity of cefiderocol with both approved and developmental β-lactam/β-lactamase inhibitor combinations against highly resistant isolates—including those resistant to both meropenem and the latest inhibitor combinations (reference).

Methods and Experimental Design Insights

The authors performed susceptibility testing on the collected Enterobacterales isolates, including Klebsiella spp., Escherichia coli, and Enterobacter spp., with a focus on bloodstream infection sources. Meropenem resistance was stringently defined using a high-dose minimum inhibitory concentration (MIC) threshold (MIC >8 mg/L), ensuring clinical relevance. Cefiderocol susceptibility was assessed alongside approved and investigational β-lactam/β-lactamase inhibitor combinations, such as cefepime-taniborbactam and aztreonam-avibactam.

For isolates resistant to meropenem but susceptible to cefiderocol, PCR was used to identify carbapenemase and other β-lactamase genes. Cefiderocol-resistant strains underwent whole-genome sequencing to uncover underlying resistance mechanisms, including mutations in iron uptake systems and cell wall synthesis enzymes.

Core Findings and Why They Matter

Cefiderocol demonstrated high in vitro activity against the entire Enterobacterales cohort, with susceptibility rates of 98.1%—significantly outperforming approved β-lactam/β-lactamase inhibitor combinations (which ranged from 78.1% to 97.4%). Among meropenem-resistant isolates, cefiderocol retained 87.8% susceptibility, a rate that was consistently higher than any single approved inhibitor combination (0%–71.6%) and comparable to newer agents (93.2%–98.6%). For the most refractory isolates—those resistant to both meropenem and β-lactam/β-lactamase inhibitors—cefiderocol still achieved 61.9%–65.9% susceptibility.

Mechanistically, most meropenem-resistant isolates harbored carbapenemase genes, predominantly Klebsiella pneumoniae carbapenemase (KPC). Cefiderocol activity was generally preserved in the presence of these enzymes, except for certain strains producing metallo-β-lactamases (notably NDM), AmpC, or non-carbapenemase OXA β-lactamases. Notably, cefiderocol-resistant isolates often exhibited multiple resistance determinants, including mutations affecting iron uptake and penicillin-binding proteins (Santerre Henriksen et al., 2024).

These data underscore cefiderocol’s utility as a potent single agent in the face of expanding resistance, offering researchers a validated model compound for investigating antimicrobial activity against Gram-positive and Gram-negative bacteria, and informing clinical strategies where treatment options are limited.

Comparison with Internal Research and Related Literature

Internal articles reinforce the translational value of robust, broad-spectrum cephalosporins such as Cefepime (BMY-28142) in advanced infection models. For instance, Cefepime (BMY-28142): Unlocking New Frontiers in CNS Infection Models discusses how the compound’s blood-brain barrier penetration supports central nervous system infection research, particularly when modeling adaptive resistance and neurotoxicity. Similarly, Cefepime (BMY-28142): Optimizing Research on Gram-Positiv... highlights the reproducibility and versatility of Cefepime in tackling multidrug-resistant pathogens in both CNS and systemic infection models.

These perspectives align with the reference study’s focus on using well-characterized antimicrobial agents as benchmarks for research into new resistance mechanisms and for validating infection models, especially those involving difficult-to-treat phenotypes. Furthermore, molecular epidemiology studies such as Transmission Dynamics of Carbapenemase Genes in CREC provide context for the observed prevalence and mobility of resistance genes, supporting comprehensive modeling of resistance dynamics in the lab.

Protocol Parameters

• Isolate selection: Source Enterobacterales from bloodstream or relevant clinical samples to ensure model relevance for systemic infection research.
• Resistance definition: Use high-dose MIC thresholds (e.g., MIC >8 mg/L for meropenem) to identify truly resistant phenotypes, as in the reference study.
• Susceptibility testing: Incorporate cefiderocol and comparator agents such as cefepime-taniborbactam and aztreonam-avibactam following standardized panels.
• Genotypic analysis: Employ PCR for routine detection of β-lactamase genes; apply whole-genome sequencing for isolates with unexplained resistance profiles.
• Workflow validation: For CNS infection or neurotoxicity studies, select compounds like Cefepime with well-documented blood-brain barrier penetration and standardized dosing guidance (product information).
• Storage and preparation: Prepare antimicrobial solutions immediately prior to use and store solid compounds at -20°C to preserve activity, as recommended for Cefepime (BMY-28142).

Limitations and Transferability

The study’s strengths include its multicenter design and large, well-characterized isolate collection. However, as an in vitro investigation, it does not address pharmacokinetic or pharmacodynamic variables in vivo, nor does it evaluate clinical outcomes. Susceptibility breakpoints and resistance mechanisms may vary regionally and over time as new resistance determinants emerge. Researchers aiming to translate these findings to animal or cell-based infection models should therefore incorporate local epidemiology data and consider host-pathogen interactions not captured in vitro. Furthermore, the complexity of resistance—particularly in strains harboring multiple β-lactamase genes and iron uptake mutations—necessitates ongoing surveillance and method adaptation.

Research Support Resources

To facilitate rigorous modeling of antimicrobial activity against Gram-positive and Gram-negative bacteria—including in challenging settings such as central nervous system infection research or neurotoxicity studies—laboratories may utilize Cefepime (BMY-28142) (SKU BA1013) from APExBIO. With its documented blood-brain barrier penetration and broad-spectrum profile, this compound is well-suited for experimental validation and resistance mechanism assays. Researchers are advised to follow best practices for compound handling and dosing, as outlined in the product dossier, and to integrate molecular analysis techniques for comprehensive resistance characterization. These workflow strategies, in combination with insights from the referenced study, can empower translational research on emerging multidrug-resistant pathogens.